<DOC>
	<DOCNO>NCT00058227</DOCNO>
	<brief_summary>This phase I trial study side effect , best way give , best dose alvocidib give together fludarabine phosphate rituximab treat patient previously untreated relapsed lymphoproliferative disorder mantle cell lymphoma . Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy alvocidib fludarabine use different way stop cancer cell divide stop grow die . Combining monoclonal antibody therapy chemotherapy may kill cancer cell .</brief_summary>
	<brief_title>Alvocidib , Fludarabine Phosphate , Rituximab Treating Patients With Lymphoproliferative Disorders Mantle Cell Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safe tolerate dose flavopiridol ( alvocidib ) combination standard dose rituximab fludarabine ( fludarabine phosphate ) patient indolent B-cell lymphoproliferative disorder mantle cell lymphoma . II . To assess toxicity combination regimen flavopiridol , rituximab fludarabine patient indolent B-cell lymphoproliferative disorder mantle cell lymphoma . III . To determine safety , toxicity efficacy administer flavopiridol 30-minute bolus follow 4-hour infusion , combination rituximab fludarabine patient indolent B-cell lymphoproliferative disorder mantle cell lymphoma . SECONDARY OBJECTIVES : I . To determine pharmacokinetics combination regimen flavopiridol , rituximab fludarabine patient indolent B-cell lymphoproliferative disorder mantle cell lymphoma . II . To determine pharmacodynamics combination regimen flavopiridol , rituximab fludarabine patient indolent B-cell lymphoproliferative disorder mantle cell lymphoma . OUTLINE : This dose-escalation study alvocidib . Patients receive fludarabine phosphate intravenously ( IV ) 15-30 minute day 1-5 rituximab IV 3-4 hour day 1 . Alvocidib administer IV 60 minute day 1 cohort 1 ; day 1 2 cohort 2 ; day 1 , 2 , 3 cohort 3 . In cohort 4 5 , patient receive fludarabine phosphate rituximab alvocidib IV 30 minute IV 4 hour day 1 course 2-6 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 37 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Histologically confirm mantle cell lymphoma OR indolent Bcell lymphoproliferative disorder follow type : Chronic lymphocytic leukemia Small lymphocytic lymphoma Follicular center cell nonHodgkin 's lymphoma ( grade I II ) Marginal zone lymphoma Waldenstrom 's macroglobulinemia Hairy cell leukemia Previously untreated relapsed/refractory disease No evidence histological transformation intermediategrade aggressive lymphoma CD20 positive immunoperoxidase flow cytometry Evaluable disease presence 1 follow criterion : Absolute lymphocyte count great 5,000/mm^3 At least 1 measurable node great 2 cm compute tomography ( CT ) scan OR measurable disease lymphoid structure ( spleen ) Bone marrow involvement ( great 20 % marrow cellularity ) Performance status Eastern Cooperative Oncology Group ( ECOG ) 02 See Disease Characteristics Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9.0 g/dL Bilirubin great 2 time normal Aspartate aminotransferase ( AST ) great 2 time normal Creatinine great 2.0 mg/dL Creatinine clearance least 50 mL/min No renal dysfunction would impair tolerance compliance study therapy No cardiac dysfunction would impair tolerance compliance study therapy No pulmonary dysfunction would impair tolerance compliance study therapy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No chronic gastrointestinal disease ( e.g. , Crohn 's disease , ulcerative colitis , short gut syndrome ) would impair tolerability compliance therapy No neurological psychiatric dysfunction would impair tolerability compliance study therapy At least 6 week since prior nitrosourea mitomycin No 6 prior course fludarabine No concurrent corticosteroids antiemetic At least 4 week since prior therapy disease No 3 prior treatment disease ( include steroid alone )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>